Cytokine storm syndrome in coronavirus disease 2019: A narrative review

J Intern Med. 2021 Feb;289(2):147-161. doi: 10.1111/joim.13144. Epub 2020 Jul 22.

Abstract

Cytokine storm syndrome (CSS) is a critical clinical condition induced by a cascade of cytokine activation, characterized by overwhelming systemic inflammation, hyperferritinaemia, haemodynamic instability and multiple organ failure (MOF). At the end of 2019, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, and rapidly developed into a global pandemic. More and more evidence shows that there is a dramatic increase of inflammatory cytokines in patients with COVID-19, suggesting the existence of cytokine storm in some critical illness patients. Here, we summarize the pathogenesis, clinical manifestation of CSS, and highlight the current understanding about the recognition and potential therapeutic options of CSS in COVID-19.

Keywords: COVID-19; SARS-CoV-2; cytokine storm syndrome; recognition; treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • COVID-19 / blood
  • COVID-19 / diagnosis*
  • COVID-19 / therapy
  • Coronavirus Infections / blood
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / therapy
  • Critical Illness
  • Cytokine Release Syndrome / blood
  • Cytokine Release Syndrome / diagnosis*
  • Cytokine Release Syndrome / therapy
  • Cytokines / blood
  • Dendritic Cells / immunology
  • Disease Progression
  • Early Diagnosis
  • Early Medical Intervention
  • Endothelial Cells / immunology
  • Humans
  • Multiple Organ Failure
  • Prognosis

Substances

  • Cytokines